MOLN

Molecular Partners

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

consensus rating "Buy"

Bearish Abandoned Baby

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About MOLN

Molecular Partners Ag

A Swiss biotech company that develops engineered protein therapy for Covid-19 and cancer

Industry

Biological Technology

Established Date

11/22/2004

Listing Date

06/16/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

159

Fiscal Year Ends

12-31

Website

www.molecularpartners.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland

Business

Focus on infectious diseases, oncology and ophthalmology

Introduction

Molecular Partners AG was incorporated in Switzerland on November 22, 2004. The company is a clinical-stage biopharmaceutical company applying its groundbreaking DARPin product candidates to the treatment of serious diseases, with a current focus on infectious diseases, oncology and ophthalmology. The company's DARPin platform is designed using anchor repeat proteins, allowing the company to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially providing patients with products with higher efficacy and fewer adverse events.

Company Financials

EPS

MOLN has released its 2021 Q4 earnings. EPS was reported at -2.23, versus the expected -1.83, missing expectations. The chart below visualizes how MOLN has performed over recent quarters, highlighting trends in earnings surprises.